Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Tests Evaluated for Screening for Toxoplasmosis

By LabMedica International staff writers
Posted on 11 Jan 2011
Three blood serum tests have been evaluated of their potential as screening methods for the diagnosis of toxoplasmosis in pregnant women. More...


The assays were the classical Sabin–Feldman dye test (DT), an immunosorbent agglutination assay for immunoglobulin-M (ISAGA-IgM) and an automated electrochemiluminescence immunoassay (ECI) for both IgM and immunoglobulin-G (IgG).

Scientist at the Medical University of Vienna (Vienna, Austria), analyzed serum samples from 927 pregnant women, including 100 negative, 706 chronic, and 121 acute infections of Toxoplasma gondii.

The combination of the Elecsys Toxo IgG and IgM immunoassays (ECI) demonstrated high sensitivity and specificity of 97.1% and 100.0%, respectively, and a positive and negative predictive value of 100.0% and 81.3%, respectively.

The Elecsys Toxo IgG and IgM immunoassays (Roche Diagnostics, Mannheim, Germany) were found to be easy-to-use and fast test systems that provide results within 18 minutes, and therefore appropriate for high-throughput analysis in daily routine. The assay was designed to be used on Roche's "cobas e” immunoassay analyzers for the in vitro quantitative determination of IgG and IgM antibodies.

Untreated infection with the protozoan T. gondii during pregnancy can lead to fetal infection with serious consequences. T. gondii may cause a broad spectrum of clinical diseases, varying from subclinical infection to congenital toxoplasmosis with severe symptoms such as retinochoroiditis, intracerebral calcifications, hydrocephalus, and mental retardation. The transmission of the parasite occurs from the ingestion of insufficiently cooked meat or contact with cats.

The authors concluded that the Elecsys test system is appropriate for first-line serologic prenatal screening carried out within the first trimester and in seronegative pregnant women, and follow-up serology is recommended at eight-week intervals to identify seroconversions. However, for discrimination between chronic and acute infection, retesting by a reference laboratory should be mandatory to discriminate between pre- and postconceptional infection to start antiparasitic treatment to avoid mother-to-fetus transmission and severe sequelae. The study was published in December 2010, in Diagnostic Microbiology and Infectious Disease.

Related Links:

Medical University of Vienna
Roche Diagnostics





Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.